BridgeBio Pharma Q3 2026 Results: Net Loss of $56.7M, Loss Narrows
BridgeBio Pharma reported a significant increase in total revenues to $791.4 million for the first nine months of 2026, driven primarily by net product revenue from Attruby and Beyonttra. Despite the revenue growth, the company maintained a net loss of $382.9 million due to high research and development and selling expenses, though this was an improvement from the $538.3 million loss in the prior year period.
- Key figure
- Net loss $56.7M